Current concepts: Nanomedicine

New England Journal of Medicine

Volumn 363, Issue 25, 2010, Pages 2434-2443

  Kim, Betty Y S ^a,b,d,e,g   Rutka, James T ^d,e,f,g   Chan, Warren C W ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Department of Materials Science and Engineering ^*  (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Department of Surgery   (Canada)

^f Arthur and Sonia Labatt Brain Tumour Research Centre   (Canada)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; AURIMMUNE; AUROSHELL; CALAA 01; DOXORUBICIN; FERUCARBOTRAN; GOLD; GOLD NANOPARTICLE; IRON OXIDE; NANOMATERIAL; NANOSHELL; NANOTHERM; PACLITAXEL; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VERIGENE; VIVAGEL; DIAGNOSTIC AGENT;

ABDOMINAL PAIN; BACKACHE; CHEMICAL COMPOSITION; CYTOPENIA; DIAGNOSTIC VALUE; DYSURIA; FEVER; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NEPHROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; URINE RETENTION; URTICARIA; VASODILATATION; CLINICAL TRIAL (TOPIC); INSTRUMENTATION; METHODOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; NANOMEDICINE; NANOSTRUCTURES;

EID: 78650196945     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra0912273     Document Type: Review

References (40)

1. Terminology for nanomaterials. Publicly available specification 136. London: British Standards Institute, 2007. (http://www.nanointeract.net/x/file/ PAS%20136.pdf.)
2. Xia Y, Xiong YJ, Lim B, Skrabalak SE. Shape-controlled synthesis of metal nanocrystals: simple chemistry meets complex physics? Angew Chem Int Ed Engl 2009;48:60-103.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60. (Pubitemid 350223348)
4. Council of the Canadian Academies. Small is different: a science perspective on the regulatory challenges of the nanoscale. July 2008. (http://www.nanolawreport.com/JulyCanadaReport.pdf.)
5. Thorek DLJ, Chen A, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 2006;34:23-38.
6. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R, Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat Methods 2008;5:763-75.
7. McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005;2:312-8.
8. Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70.
9. Sperling RA, Gil PR, Zhang F, Zanella M, Parak WJ. Biological applications of gold nanoparticles. Chem Soc Rev 2008;37:1896-908.
10. Liu ZA, Li XL, Tabakman SM, Jiang KL, Fan SS, Dai HJ. Multiplexed multicolor Raman imaging of live cells with isotopically modified single walled carbon nanotubes. J Am Chem Soc 2008;130:13540-1.
11. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998;95:4607-12.
12. Prencipe G, Tabakman SM, Welsher K, et al. PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. J Am Chem Soc 2009;131:4783-7.
13. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-15.
14. Libutti SK, Paciotti GF, Myer L, et al. Preliminary results of a phase I clinical trial of CYT-6091: a pegylated colloidal gold-TNF nanomedicine. J Clin Oncol 2007;25:Suppl:163s. abstract.
15. Visaria RK, Griffin RJ, Williams BW, et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther 2006;5:1014-20.
16. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16.
17. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
18. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999;9:228-32. (Pubitemid 29115346)
19. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009;9:1909-15.
20. Posthuma-Trumpie GA, Korf J, van Amerongen AV. Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats: a literature survey. Anal Bioanal Chem 2009;393:569-82.
21. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 2003;301:1884-6.
22. Lefferts JA, Jannetto P, Tsongalis GJ. Evaluation of the Nanosphere Verigene System and the Verigene F5/F2/MTHFR Nucleic Acid Tests. Exp Mol Pathol 2009;87:105-8.
23. Thaxton CS, Elghanian R, Thomas AD, et al. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A 2009;106:18437-42.
24. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 2003;100:13549-54.
25. Huang X, Neretina S, El-Sayed MA. Gold nanorods: from synthesis and properties to biological and biomedical applications. Adv Mater 2009;21:4880-910.
26. Helms B, Meijer EW. Dendrimers at work. Science 2006;313:929-30.
27. Nel AE, Madler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009;8:543-57.
28. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2004;4:11-8.
29. Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008;3:423-8.
30. Hediel JD, Yu Z, Liu JYC, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase sub-unit M2 siRNA. Proc Natl Acad Sci U S A 2007;104:5715-21.
31. Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia 2007;23:315-23. (Pubitemid 46860598)
32. Schipper ML, Nakayama-Ratchford N, Davis CR, et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol 2008;3:216-21.
33. Hauck TS, Anderson RE, Newbigging S, Chan WCW. In vivo quantum dot toxicity assessment. Small 2010;6:138-44.
34. Lidke DS, Nagy P, Heintzmann R, et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 2004;22:198-203.
35. Chattopadhyay PK, Price DA, Harper TF, et al. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med 2006;12:972-7.
36. Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004;22:93-7.
37. Gao X, Cui Y, Levenson R, Chung L, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969-76.
38. Suh WH, Suh Y-H, Stucky GD. Multi-functional nanosystems at the interface of physical and life sciences. Nano Today 2009;4:27-36.
39. Park JH, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 2009;8:331-6.
40. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett 2005;5:2578-85.